Lantern Pharma (LTRN) EBIT (2020 - 2026)
Lantern Pharma's (LTRN) quarterly EBIT came in at -$3.4 million in Q1 2026, up 28.67% YoY from -$2.6 million in Q1 2025, and up 18.98% on a QoQ basis from -$4.2 million in Q4 2025.
Lantern Pharma (LTRN) EBIT (2020 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 7 years of EBIT data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly EBIT rose 28.67% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.6 million (up 21.87% YoY) and the FY2025 annual result came in at -$18.0 million, up 19.08% from the prior year.
- EBIT rose to -$3.4 million in Q1 2026, from -$4.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$2.1 million in Q3 2022 to a low of -$5.9 million in Q4 2024.
- A 5-year average of -$4.5 million and a median of -$4.4 million in 2022 frame the typical range for EBIT.
- The widest YoY moves for EBIT: up 48.29% in 2022, down 77.28% in 2022.
- Tracing LTRN's EBIT over 5 years: stood at -$3.8 million in 2022, then slipped by 27.47% to -$4.9 million in 2023, then dropped by 20.89% to -$5.9 million in 2024, then increased by 28.72% to -$4.2 million in 2025, then gained by 18.98% to -$3.4 million in 2026.
- The last three EBIT figures came in at -$3.4 million (Q1 2026), -$4.2 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | -3.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.41 Mn |
| Dec 31, 2025 | -4.20 Mn |
| Sep 30, 2025 | -4.35 Mn |
| Jun 30, 2025 | -4.65 Mn |
| Mar 31, 2025 | -4.77 Mn |
| Dec 31, 2024 | -5.90 Mn |
| Sep 30, 2024 | -5.18 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Mar 31, 2024 | -5.73 Mn |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -3.52 Mn |
| Jun 30, 2023 | -5.19 Mn |
| Mar 31, 2023 | -4.29 Mn |
| Dec 31, 2022 | -3.83 Mn |
| Sep 30, 2022 | -2.15 Mn |
| Jun 30, 2022 | -4.39 Mn |
| Mar 31, 2022 | -4.07 Mn |
| Dec 31, 2021 | -3.51 Mn |
| Sep 30, 2021 | -4.15 Mn |
| Jun 30, 2021 | -2.48 Mn |